|
Study Investigating the Efficacy and Safety of UV1 Vaccination in Combination with Nivolumab and Ipilimumab as First-line Treatment of Patients with Unresectable or Metastatic Melanoma (UV1-202) |
II |
|
|
Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer (PMR) |
|
|
|
Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer (ELECTRA) |
I |
|
|
Study of Adagloxad Simolenin (OBI-822) and OBI-821 Versus Placebo Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients (TNBC) Following Neoadjuvant or Adjuvant Chemotherapy |
|
|
|
Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer; (AFT-19) |
III |
|
|
Study of ASP1948, Targeting Immune Modulatory Receptor in Subjects with Advanced Solid Tumors (1948-CL-0101) |
I |
|
|
Study of ASP1948, Targeting Immune Modulatory Receptor in Subjects with Advanced Solid Tumors (1948-CL-0101) |
I |
|
|
Study of ASP1948, Targeting Immune Modulatory Receptor in Subjects with Advanced Solid Tumors (1948-CL-0101) |
I |
|
|
Study of ASP1948, Targeting Immune Modulatory Receptor in Subjects with Advanced Solid Tumors (1948-CL-0101) |
I |
|
|
Study of ASP1948, Targeting Immune Modulatory Receptor in Subjects with Advanced Solid Tumors (1948-CL-0101) |
I |
|
|
Study of ASP1948, Targeting Immune Modulatory Receptor in Subjects with Advanced Solid Tumors (1948-CL-0101) |
I |
|
|
Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–SmallCell Lung Cancer Patients Who Have Progressed on Crizotinib (18129) |
III |
|
|
Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab in subjects with Locally advanced or Metastatic Solid Tumors (XL184-021) |
I |
|
|
Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab in subjects with Locally advanced or Metastatic Solid Tumors (XL184-021) |
I |
|
|
Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab in subjects with Locally advanced or Metastatic Solid Tumors (XL184-021) |
I |
|
|
Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (MK7339-001) |
III |
|
|
Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (GI005) |
II |
|
|
Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (EA2182) |
II |
|
|
Study of Erdafitinib Compared with Vinfluine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberations (17133) |
III |
|
|
Study Of High Dose Interleukin 2 Vs High Dose Interleukin 2 Plus Entinostat In Untreated Advanced Renal Cell Carcinoma (HCRN GU17-289) |
II |
|
|
Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors (PCYC-1128-CA) |
I |
|
|
Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (MEL 16-252 SALVO) |
II |
|
|
Study of mFolfox6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatci Colorectal Cancer (GI004) |
III |
|
|
Study of Neoadjuvant Cemiplimab for Stage II to IV (M0) Cutaneous Squamous Cell Carcinoma (R2810-ONC-1901) |
II |
|
|
Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer (EA2165) |
II |
|
